Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.835
-0.005 (-0.27%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Heron Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Heron Therapeutics stock have an average target of 5.67, with a low estimate of 4.00 and a high estimate of 7.00. The average target predicts an increase of 208.99% from the current stock price of 1.84.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Heron Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +117.98% | Apr 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +117.98% | Feb 28, 2025 |
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +117.98% | Dec 4, 2024 |
| Needham | Needham | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +117.98% | Nov 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +172.48% | Sep 25, 2024 |
Financial Forecast
Revenue This Year
161.33M
from 144.29M
Increased by 11.81%
Revenue Next Year
186.81M
from 161.33M
Increased by 15.79%
EPS This Year
-0.04
from -0.09
EPS Next Year
0.07
from -0.04
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 170.1M | 197.8M | 224.5M | ||
| Avg | 161.3M | 186.8M | 211.6M | ||
| Low | 151.9M | 174.3M | 197.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 17.9% | 22.6% | 20.2% | ||
| Avg | 11.8% | 15.8% | 13.3% | ||
| Low | 5.3% | 8.1% | 5.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 0.08 | 0.22 | ||
| Avg | -0.04 | 0.07 | 0.20 | ||
| Low | -0.06 | 0.05 | 0.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 232.6% | ||
| Avg | - | - | 200.0% | ||
| Low | - | - | 166.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.